Nasdaq gnlx.

Find the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Stock Quote & Chart. NASDAQ: GNLX. $11.90. Nov 30, 2023 4:00 PM EST. Change. +0.2 (+1.71%). Volume. 86,169. Today's Open. $11.79. Previous Close. $11.70.Jun 29, 2023 · WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ... WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...WebWESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...Web

Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...Dec 1, 2023 · A high-level overview of Genelux Corporation (GNLX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.Jan 21, 2023 · Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ...

Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile …WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid …

GNLX Genelux Corporation Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Genelux Corporation 10% owner discloses sale of 49,987 shares (NASDAQ:GNLX). From Seeking Alpha Oct 26, 2023. Genelux Corporation (GNLX) 10% owner, Aladar ...

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023. "I am excited to welcome Lourie to Genelux as our new Chief Financial Officer," said …GNLX U.S.: Nasdaq Genelux Corp. Watch list Set a price target alert After Hours Last Updated: Oct 10, 2023 6:54 p.m. EDT Delayed quote $ 23.00 0.97 4.40% After Hours Volume: 3.98K Advanced...WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 ...2 days ago · Genelux IPO prices at bottom of range. Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the Nasdaq under the symbol GNLX. With 2.5 million sha... 11 months ago - Market Watch. As of this writing, Genelux Corp (NASDAQ:GNLX) shares are trading at above $22.30 with a 52-week range of $5.35 to $39.27, giving the company a market capitalization of more than $527 million. 2 ...Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...

57.59%. Get the latest Genelux Corp (GNLX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Jul 28, 2023 · Shares of Genelux ( GNLX -7.61%) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock ... GNLX. --Genelux Corporation, a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share ...Given GNLX’s positive Phase 2 trial results to-date, my outlook on IPO is a Buy for patient, risk-tolerant life science investors with a long-term hold time frame. ... (NASDAQ:GNLX) was founded ...WebIn terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.View real-time GNLX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...WebGenelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ...

Aclaris Therapeutics (NASDAQ:ACRS) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and …The public float for GNLX is 19.35M, and currently, shorts hold a 4.47% of that float. The average trading volume for GNLX on November 20, 2023 was 226.90K shares. GNLX) stock’s latest price update. The stock price of Genelux Corp (NASDAQ: GNLX) has dropped by -9.53 compared to previous close of 13.12.

Jul 10, 2023 · WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in ... Based on analysts offering 12 month price targets for GNLX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Sign in to your ...Genelux (Nasdaq:GNLX) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech GNLX Genelux NasdaqCM:GNLX …About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Bed Bath & Beyond Inc. Common Stock. 1.74%.WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...WebJul 10, 2023 · WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in ... HC Wainwright started coverage of Genelux ( NASDAQ: GNLX) with a buy rating, stating that it believed the company’s lead oncolytic virus Olvi-Vec is “underappreciated” and could lead to a ...26. 10. 2023 ... Genelux raised $15.9 million in January pricing shares at $6 each. The stock (NASDAQ:GNLX) closed at $18.69 on Oct. 25, a 211.5% increase. Also ...

Genelux Corporation (GNLX) Stock Price, Quote, News & Analysis Black Friday is here! Save 45% on Premium AND Alpha Picks now » GNLX Genelux …

Top 25 Mutual Funds Where Should I Retire? Top 25 ETFs MarketWatch Picks Close Search Overlay $749.20K Ex-Dividend Date % of Float Shorted Oct. 27, 2023 at 1:30 …

GNLX Genelux Corporation Form 4 - Statement of changes in beneficial ownership of securities. SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF ...WESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in ...WebIn the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings.The latest price target for Genelux ( NASDAQ: GNLX) was reported by Maxim Group on Tuesday, September 12, 2023. The analyst firm set a price target for 40.00 expecting GNLX to rise to within 12 ...View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news.View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news.Jan 27, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Genelux stock is Buy based on the current 3 buy ratings for GNLX. The average twelve-month price prediction for Genelux is $25.00 with a high price target of $40.00 and a low price target of $10.00. Learn more on GNLX's analyst rating history. CIPhotos. Genelux ( NASDAQ: GNLX) is an immuno-oncology frontrunner that presents a promising investment opportunity in the fight against cancer. With its cutting-edge technology platform, strong ...WebWESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President ...WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ...Genelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ...Web

Stock analysis for Genelux Corp (GNLX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...Genelux Co. ( NASDAQ:GNLX – Free Report) – Analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for shares of Genelux in a …Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.Instagram:https://instagram. day trader stocksnyse ionqbanks to invest in right nowhpso insurance reviews The public float for GNLX is 19.35M, and currently, shorts hold a 4.47% of that float. The average trading volume for GNLX on November 20, 2023 was 226.90K shares. GNLX) stock’s latest price update. The stock price of Genelux Corp (NASDAQ: GNLX) has dropped by -9.53 compared to previous close of 13.12.add_box. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...Web ssnchyg etf dividend Le titre Ampio Pharmaceuticals (AMEX: AMPE) a chuté vendredi de 45,05% à 3,17 dollars lors de la session ordinaire. L’action Intelligent Bio Solutions (NASDAQ: … yellow trucking ceo pay GNLX | Complete Genelux Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.WebWESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...